NeuroSense Therapeutics shareholders authorized board to pursue reverse stock split range 1-for-4 to 1-for-40

• NeuroSense Therapeutics held a special shareholder meeting on Aug. 26, 2026.
• Shareholders authorized the board to implement one or more reverse share splits, at an aggregate ratio between 1-for-4 and 1-for-40.
• The board will set the exact ratio and any effective date within 12 months; no split has been executed.
• Investors also endorsed that no amendment to the articles of association is required for any such reverse split.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-094389), on August 27, 2026, and is solely responsible for the information contained therein.